- Korea’s first manufacturing center specialized in iPSC-derived cell therapy products
-
Therabest is the first in Korea to establish its‘Thera-Cell Center’, specialized in the production of iPSC-derived cell therapy products.
Thera-Cell Center (total area 1,123 m2) is located in the Anyang SKV1 Knowledge Industry Center and consists of a production facility including three manufacturing rooms, a cell cryostorage room, and a dedicated QC laboratory separate from the manufacturing area.
-
Location
Anyang SKV1 Knowledge Industry Center -
Size
1,123 m2 -
Configuration
three manufacturing rooms, a cell cryostorage room and a QC laboratory
- Robust Compliance to Meet cGMP Requirements
-
Thera-Cell Center was designed to meet the specific requirements for the iPSC-derived cell therapy product manufacturing process (Gene editing, Differentiation, and Mass production), and is currently operated in a compliance with the KFDA, USFDA, and EMDA guidelines for cGMP certification.
We are planning to produce the first EiNK™ pipeline in the second half of 2022, and aiming to produce additional EiNK™ pipelines through joint cooperation with leading companies in the pharmaceutical industry.
Facility Introduction
.jpg)
.jpg)